AstraZeneca said on Monday its experimental precision drug developed with Japan's Daiichi Sankyo did not significantly ...

AstraZeneca said on Monday its experimental precision drug developed with Daiichi Sankyo did not significantly improve ...

We recently compiled a list of the 10 Best Growth Stocks To Buy According To George Soros. In this article, we will look at ...

A cancer drug being developed by AstraZeneca failed to "achieve statistical significance" in helping patients live longer ...

AstraZeneca and Daiichi Sankyo’s TROP2-directed antibody-drug conjugate (ADC) has again failed to improve overall survival ...

The AstraZeneca PLC ADR AZN slipped 1.58% to $77.14 Monday, on what proved to be an all-around great trading session for the ...

AstraZeneca PLC AZN shares dropped 1.66% to £115.84 Monday, on what proved to be an all-around great trading session for the ...

AstraZeneca released results from the TROPION-Breast01 Phase 3 trial of datopotamab deruxtecan, showing no statistically ...

A new AstraZeneca drug has failed to extend significantly the lives of breast cancer patients in a blow to the company’s ...

The approved indication involves using durvalumab in combination with chemotherapy as a neoadjuvant treatment, followed by ...

This approval allows Durvalumab to be used together with chemotherapy before surgery, and then as a single treatment ...

AstraZeneca stock slumped Monday after its Daiichi Sankyo-partnered drug missed its mark in a study of patients with breast ...